A clinical trial comparing two weight loss tablets for type 2 diabetes patients shows orforglipron, manufactured by Eli Lilly, outperformed Wegovy in both blood sugar control and weight reduction. Over 12 months, participants taking orforglipron lost 6-8% of their body weight compared to 4-5% with oral semaglutide, though orforglipron caused more gastrointestinal side effects. The medication is still under regulatory review and awaiting approval for use in Australia.

See omnystudio.com/listener for privacy information.

See omnystudio.com/listener for privacy information.